糖尿病对左心室辅助装置植入术后短期、中期和长期死亡率的影响
一项在以色列大型三级医疗中心开展的观察性队列研究,纳入2006至2020年间接受连续流左心室辅助装置(LVAD)植入的154例患者,比较有无2型糖尿病患者的短期、中期和长期死亡率。结果显示糖尿病组5年死亡率显著更高(38.7% vs 24.4%,P=0.038),糖尿病是长期5年死亡率的独立预测因素(HR 2.09,CI 1.34-2.84,P=0.004)。
要点
- 糖尿病组与无糖尿病组30天、1年、3年死亡率无统计学显著差异。
- 糖尿病组5年死亡率显著高于无糖尿病组(38.7% vs 24.4%,P=0.038)。
- 糖尿病是LVAD植入术后长期5年死亡率的独立预测因素(HR 2.09)。
核心结论
- 糖尿病患者与非糖尿病患者LVAD植入术后30天及短期、中期死亡率相似。
- 糖尿病患者死亡风险在LVAD植入3年后开始增加。
- 糖尿病是LVAD植入术后长期5年死亡率的独立预测因素。
研究设计与样本
- 在以色列一家大型三级医疗中心开展的观察性队列研究。
- 纳入2006年至2020年间接受连续流LVAD植入的患者,数据提取自科室数据库。
- 共纳入154例患者,分为无糖尿病组(88例)和糖尿病组(66例)。
- 比较两组短期(30天和3个月)、中期(1年和3年)及长期(5年)死亡率。
- 平均随访时长为38.2 ± 30.3个月。
主要发现
- 30天死亡率糖尿病组16.1% vs 无糖尿病组9.8%(P = 0.312),差异未达统计学显著。
- 1年死亡率糖尿病组24.2% vs 无糖尿病组17.3%(P = 0.399),差异未达统计学显著。
- 3年死亡率糖尿病组30.6% vs 无糖尿病组21.9%(P = 0.127),差异未达统计学显著。
- 5年死亡率糖尿病组38.7% vs 无糖尿病组24.4%(P = 0.038),糖尿病组显著更高。
- 回归分析显示糖尿病是长期死亡率的预测因素(风险比2.09,置信区间1.34-2.84,P = 0.004)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Type 2 diabetes mellitus (DM) is a frequent comorbidity among patients suffering from advanced heart failure necessitating a left ventricular assist device (LVAD) implant. The goal of this study was to evaluate the impact of type 2 DM on early and long-term outcomes of patients following an LVAD implant. METHODS: We performed an observational cohort study in a large tertiary care centre in Israel. All data of patients who underwent a continuous flow LVAD implant between 2006 and 2020 were extracted from our departmental database. Patients were divided into 2 groups: group I (patients without diabetes) and group II (patients with diabetes). We compared short-term (30-day and 3-month) mortality, intermediate-term (1- and 3-year) mortality and long-term (5 year) mortality between the 2 groups. RESULTS: The study population included 154 patients. Group I (patients without diabetes) comprised 88 patients and group II (patients with diabetes) comprised 66 patients. The mean follow-up duration was 38.2 ± 30.3 months. Short- and intermediate-term mortality (30 days, 1 year and 3 years) was higher in the group with DM compared with the group without DM but did not reach any statistically significant difference: 16.1% vs 9.8% (P = 0.312), 24.2% vs 17.3% (P = 0.399) and 30.6% vs 21.9% (P = 0.127) respectively. Long-term 5-year mortality was significantly higher in the group with DM compared to the group without: 38.7% vs 24.4% (P = 0.038). Furthermore, predictors of long-term mortality included diabetes (hazard ratio 2.09, confidence interval 1.34-2.84, P = 0.004), as demonstrated by regression analysis. CONCLUSIONS: Patients with diabetes and those without diabetes have similar 30-day and short- and intermediate-term mortality rates. The mortality risk of diabetic patients begins to increase 3 years after an LVAD implant. Diabetes is an independent predictor of long-term, 5-year mortality after an LVAD implant. CLINICAL TRIAL REGISTRATION: Ethical Committee of Sheba Medical Centre, Israel, on 2 December 2014, Protocol 4257.
引用
- Kogan A, Frogel J, Ram E, et al. The impact of diabetes on short-, intermediate- and long-term mortality following left ventricular assist device implantation. Eur J Cardiothorac Surg. 2022. PMID: 35021207. doi:10.1093/ejcts/ezab575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。